The collaboration with Omniose could potentially lead to the development of new vaccines, expanding AstraZeneca's portfolio and market presence in the vaccine segment. This news is likely to be viewed positively by investors, as it signals AstraZeneca's commitment to innovation and could lead to future revenue streams if the research is successful. However, as the collaboration is at a preclinical stage, the immediate financial impact may be limited, and the long-term benefits are uncertain.